Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Hadassah Medical Organization Ben-Gurion University of the Negev |
---|---|
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00569413 |
The current study combines a molecular genetic perspective, self report and brain imaging to the study of human sexuality in control subjects and individuals from a sexual disorder clinic. The investigators hypothesize that the variability in components of the brain dopaminergic system expressed in the mesolimbic reward system can explain variability in human sexuality, especially in desire and pleasure associated with sex.
Condition |
---|
Hypoactive Sexual Desire Disorder Erectile Dysfunction |
Study Type: | Observational |
Study Design: | Cohort, Cross-Sectional |
Official Title: | A Combined Psycho-Pharmacological and Brain Imaging Study of Human Sexuality |
Estimated Enrollment: | 40 |
Study Start Date: | April 2009 |
Estimated Study Completion Date: | October 2010 |
Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1
Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
|
2
20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
|
We intend to combine molecular genetics of the dopamine receptors (D2, D3 D4 and D5) and brain imaging using 11 C Raclopride in Positron Emission Tomography (PET). 11 C Raclopride is a ligand which binds to the dopamine receptor D2 and can measure dopamine release during pleasure or anticipatory reward associated with sex. The current proposal will measure changes in DRD2 receptor occupancy using 11 C Raclopride following explicit visual sexual desire cues in healthy control subjects and individuals who suffer from sexual dysfunction. This is in order to determine how individual genotypes modulate dopamine release in vivo in the human brain.
Ages Eligible for Study: | 21 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
A group of healthy volunteers from the general public. A group of patients who suffer from sexual disorder from a primary care clinic.
Inclusion Criteria:
Exclusion Criteria:
Contact: Aviv M. Weinstein, Ph.D | 00 972 2 6776705 | vaviv@hadassa.org.il |
Contact: Roland Chisin, M.D | 00972 2 6776705 | chisin@hadassah.org.il |
Principal Investigator: | Aviv M Weinstein, Ph.D | Hadasah Medical Organization, Jerusalem Israel |
Responsible Party: | Hadassah Medical Organization ( Prof. Roland Chisin ) |
Study ID Numbers: | 281207HMO-CTIL, First 978[1].07 |
Study First Received: | December 6, 2007 |
Last Updated: | February 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00569413 History of Changes |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Sex brain imaging dopamine sexual disorder |
Sexual Dysfunctions, Psychological Dopamine Sexual Dysfunction, Physiological Mental Disorders |
Dopamine Agents Genital Diseases, Male Hypokinesia Erectile Dysfunction |
Sexual Dysfunctions, Psychological Sexual Dysfunction, Physiological Mental Disorders |
Genital Diseases, Male Sexual and Gender Disorders Erectile Dysfunction |